OptiPin
Frag 176-191: uses, dosing & the facts
Similar to AOD-9604 but earlier formulation. Growth hormone fragment 176-191 that promotes localized fat loss without systemic HGH effects. This is an evidence-graded reference — what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Frag 176-191 — Fat loss. Similar to AOD-9604 but earlier formulation.
- • Commonly used for localized fat loss, stubborn fat reduction, body recomposition.
- • Half-life: Approximately 30 minutes.
- • Status: Research use only · not FDA-approved — an educational reference, not a dose protocol or sourcing advice.
What Frag 176-191 is
Similar to AOD-9604 but earlier formulation. Growth hormone fragment 176-191 that promotes localized fat loss without systemic HGH effects.
What Frag 176-191 is used for
- • Localized fat loss
- • Stubborn fat reduction
- • Body recomposition
- • Visceral fat targeting
- • Metabolic enhancement
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | 200-500mcg injected subcutaneously in problem areas daily |
Presented as commonly-reported patterns for information only — not a dose recommendation. Frag 176-191 dosing is a decision for a qualified clinician.
Reconstitution
Reconstitute with bacteriostatic water. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Approximately 30 minutes. Half-life drives dosing frequency and how quickly the compound clears — see it plotted on the half-life visualizer.
Cycling
Typical cycles: 8-12 weeks on, 4 weeks off.
Side effects & warnings
- • Minimal side effects
- • Generally well-tolerated
- • Possible injection site irritation
Research use only. Less studied than AOD-9604. Works best with caloric deficit and exercise.
Tracking Frag 176-191 in OptiPin
If you're tracking a Frag 176-191 protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math — all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math — all on-device.
Download on the App StoreFAQ
What is Frag 176-191?
Similar to AOD-9604 but earlier formulation. Growth hormone fragment 176-191 that promotes localized fat loss without systemic HGH effects.
What is Frag 176-191 used for?
Commonly discussed uses include: localized fat loss, stubborn fat reduction, body recomposition, visceral fat targeting, metabolic enhancement. These are reported uses, not proven outcomes or a recommendation.
How is Frag 176-191 dosed?
Commonly reported dosing: Injectable — 200-500mcg injected subcutaneously in problem areas daily. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation — Frag 176-191 is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Frag 176-191?
Reconstitute with bacteriostatic water. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Frag 176-191's half-life?
Approximately 30 minutes. Half-life shapes how often it is dosed and how quickly it clears.
What are Frag 176-191's side effects?
Reported effects include: minimal side effects, generally well-tolerated, possible injection site irritation. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Frag 176-191 on PubMed (entry point to the primary evidence base, not a specific citation).
- Frag 176-191 on ClinicalTrials.gov — registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide — categories, evidence grading, and how to run a protocol honestly.
Related
MOTS-C · SLU-PP-332 · Tesofensine · 5-Amino-1MQ · Tirzepatide (Mounjaro/Zepbound) · Reconstitution calculator · All peptides